A PLACEBO-CONTROLLED EVALUATION OF LOMEFLOXACIN IN THE TREATMENT OF BACTERIAL DIARRHEA IN THE COMMUNITY

被引：16

作者：

ELLISPEGLER, RB ^{[1
]}

HYMAN, LK ^{[1
]}

INGRAM, RJH ^{[1
]}

MCCARTHY, M ^{[1
]}

机构：

[1] DEPT MICROBIOL,DIAGNOST LAB,AUCKLAND,NEW ZEALAND

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 1995年 / 36卷 / 01期

关键词：

D O I：

10.1093/jac/36.1.259

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

We compared 40 patients taking lomefloxacin 400 mg once daily for 5 days in a double blind trial with 44 placebo takers with proven community acquired bacterial diarrhoea (85% due to Campylobacter spp.). Lomefloxacin eradicated Campylobacter spp. in 75% but did not alter clinical outcome. Twenty-eight per cent of the campylobacter isolates developed resistance. Thirty-three per cent developed side-effects. Lomefloxacin is not recommended for community-acquired bacterial diarrhoea when Campylobacter spp. predominate.

引用

页码：259 / 263

页数：5

共 6 条

[1] EMPIRIC ANTIMICROBIAL THERAPY OF DOMESTICALLY ACQUIRED ACUTE DIARRHEA IN URBAN ADULTS [J].